Loading...
•
Mar 31, 2024
Estee Lauder Q3 2024 Earnings Report
Estee Lauder's Q3 2024 results were released, showing sales and EPS growth, driven by strong performance in Asia travel retail and key brands.
Key Takeaways
Estée Lauder reported a 5% increase in net sales to $3.94 billion and a rise in diluted EPS to $0.91. Organic net sales grew by 6%, primarily driven by double-digit growth in EMEA, fueled by stronger sales in Asia travel retail. The company is confident in its renewed net sales and profit growth trajectory.
Net sales increased by 5%, reaching $3.94 billion, while organic net sales grew by 6%.
Diluted EPS increased to $0.91, and adjusted diluted EPS rose to $0.97.
Asia travel retail returned to net sales growth, contributing to overall performance.
The company affirms an inflection point of net sales growth and profitability in the second half of the fiscal year.
Estee Lauder
Estee Lauder
Estee Lauder Revenue by Segment
Estee Lauder Revenue by Geographic Location
Revenue by Segment
Skin Care Revenue
CapyFin.comMakeup Revenue
CapyFin.comFragrance Revenue
CapyFin.comHair Care Revenue
CapyFin.comOther Revenue
CapyFin.comRevenue by Geographic Location
The Americas Revenue
CapyFin.comEMEA Revenue
CapyFin.comAsia/Pacific Revenue
CapyFin.com Forward Guidance
The company forecasts net sales to increase between 5% and 9% and organic net sales to increase between 6% and 10% for the fourth quarter of fiscal year 2024. Reported diluted net earnings per common share are projected to be between $.11 and $.22. Excluding restructuring and other charges and adjustments, diluted net earnings per common share are projected to be between $.18 and $.28.
Positive Outlook
- Acceleration of organic net sales growth in the fiscal 2024 fourth quarter and high-single-digit growth in the second half.
- In Asia travel retail, a continuation of net sales growth in the fiscal 2024 fourth quarter, as well as investments to drive retail sales, following meaningful progress made through the third quarter.
- Clinique doubling down in Active Derma with new campaigns in the United States and the United Kingdom in the second half of fiscal 2024.
- Gross margin expansion in the second half of fiscal 2024 compared to the prior-year period.
- Stronger operating margin in the second half of fiscal 2024 compared to the first half, with expansion compared to the prior-year period.
Challenges Ahead
- Currency exchange rates are volatile and difficult to predict, expecting a 1% headwind due to foreign currency translation.
- The combined impact from the increases in the Company’s net interest expense and effective tax rate is expected to dilute net earnings per common share by $.21.
- The company expects to take charges associated with previously approved restructuring and other activities. For the Restructuring Program Component of the Profit Recovery Plan, the charges are estimated to be between approximately $25 million to $30 million, equal to $.05 to $.06 per diluted common share.
- The potential risks of further business disruptions in Israel and other parts of the Middle East are expected to have a dilutive impact to net earnings per common share of $.03.
- Ongoing macroeconomic headwinds, including continued softness in overall prestige beauty in mainland China, and geopolitical volatility in some areas around the world.
Revenue & Expenses
Visualization of income flow from segment revenue to net income